As of Wednesday, February 18, Cartesian Therapeutics, Inc.’s RNAC share price has dipped by 8.15%, which has investors questioning if this is right time to buy.
Factorial’s high-power, lightweight, solid-state batteries have demonstrated real-world performance, including over 1,200 km (745 miles) of driving range in vehicle testing and are being advanced ...
FREDERICK, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“we”, the “Company” or “Cartesian”), a clinical-stage biotechnology company pioneering cell therapy for ...
Special edition of Globe Magazine honors the best employers in Massachusetts BOSTON, MA, UNITED STATES, January 14, 2026 /EINPresswire.com/ — Cartesian has been ...
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development ...
The use of Cartesian and six-axis robots, as well as selective-compliance-articulated robot arms (SCARAs) is on the rise. They automate tasks to accelerate cycle times, increase throughput, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results